Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Bought by State of Wyoming

State of Wyoming boosted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 662.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 4,558 shares of the medical equipment provider's stock after buying an additional 3,960 shares during the period. State of Wyoming's holdings in Lantheus were worth $408,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of LNTH. Janus Henderson Group PLC lifted its stake in Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after purchasing an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC lifted its stake in shares of Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after acquiring an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its position in Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after acquiring an additional 435,445 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Lantheus by 2.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock worth $120,510,000 after purchasing an additional 30,891 shares during the last quarter. Finally, Swedbank AB boosted its stake in shares of Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after purchasing an additional 385,000 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This trade represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 over the last three months. Corporate insiders own 1.50% of the company's stock.

Lantheus Stock Down 1.2%

LNTH stock traded down $0.89 during trading on Monday, hitting $73.86. 671,503 shares of the company's stock traded hands, compared to its average volume of 988,498. The business has a fifty day simple moving average of $94.56 and a two-hundred day simple moving average of $92.11. The firm has a market capitalization of $5.11 billion, a P/E ratio of 12.29 and a beta of 0.23. Lantheus Holdings, Inc. has a 1 year low of $73.11 and a 1 year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Lantheus's revenue for the quarter was up .8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.69 EPS. On average, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

LNTH has been the subject of several research reports. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. B. Riley reduced their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Finally, Truist Financial decreased their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $132.67.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.